(Reuters) - In May, CV announced a plan to cut jobs and reduce the
number of sales territories to lower operating expenses.
"CV Therapeutics is in a unique position with a deep R&D
pipeline, global rights to a growing, first-in-class product in
Ranexa, and the potential 2008 approval of a second unique
compound in regadenoson. I am looking forward to helping the
company build value for these assets," Frank said in the brief
statement Monday.
Read more at Reuters.com Mergers News
number of sales territories to lower operating expenses.
"CV Therapeutics is in a unique position with a deep R&D
pipeline, global rights to a growing, first-in-class product in
Ranexa, and the potential 2008 approval of a second unique
compound in regadenoson. I am looking forward to helping the
company build value for these assets," Frank said in the brief
statement Monday.
Read more at Reuters.com Mergers News
No comments:
Post a Comment